Share: Facebook Twitter LinkedIn
Activity Provided By:

Relias LLC

Medical Crossfire®: Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent

Access Activity

Overview / Abstract:

Target Audience
This online educational activity is directed toward hematologists, primary care clinicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the management of hemophilia.

Activity Overview
Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce long-term complications of bleeding, and arrest bleeding if it occurs. Health care providers should understand the underlying etiology and pathophysiology of hemophilia A. In addition, providers should be familiar with how patients perceive their disease and how health-related and economic burdens of hemophilia A impact patients and their families.

Learning Objectives
Upon completion of this activity, you should be better able to:

Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
Develop personalized prophylactic treatment plans for patients with hemophilia A


Jan 05, 2023


Nursing CNE, Physician CME



Credits / Hours




Presenters / Authors / Faculty

Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Medical Director, Pediatric Hemophilia and Coagulation Disorders Program
Medical Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Kenneth A. Bauer, MD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Boston, MA

Michelle L. Witkop, DNP, FNP-BC
Head of Research
Vice President, Research Strategy
National Hemophilia Foundation
New York, NY

Sponsors / Supporters / Grant Providers

Physicians’ Education Resource®, LLC; Bayer Healthcare Pharmaceuticals Inc.

Keywords / Search Terms

Relias LLC Hematology-Oncology, Bleeding Disorders, Hemophilia, Pediatrics Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map